目的 研究分析舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁与焦虑共病.方法 选取本院2016年1月～2017年1月收治的76例老年抑郁与焦虑共病的患者为研究对象,随机分为对照组和实验组,每组38例.对照组患者给予艾司西酞普兰治疗,实验组患者给予舒肝解郁胶囊联合艾司西酞普兰治疗.2组患者的治疗时间均为2个月.比较分析实验组与对照组患者的相关临床指标.结果 治疗后,实验组患者的HAMD评分与HAMA评分显著低于未进行治疗前,实验组评分显著低于对照组,差异具有统计学意义(P<0.05).实验组患者的治疗有效率为86.84％显著高于对照组有效率为73.68％,差异具有统计学意义(P<0.05).实验组与对照组患者的不良反应发生例数分9例和10例,不良反应发生率差异无统计学意义.结论 舒肝解郁胶囊联合艾司西酞普兰治疗老年抑郁与焦虑共病临床效果较好,能够显著改善病情,提高治疗有效率,具有临床进一步推广和应用的意义.%Objective To study the treatment of elderly depression and anxiety in the treatment of depression and anxiety. Methods 76 cases of senile depression and anxiety co-morbidity were selected from our hospital from January 2016 to January 2017, and were randomly divided into control group and experimental group, with 38 cases in each group. The patients in the control group were treated with escitalopram, and the patients in the experimental group were treated with ascitalopram. The treatment time for both groups was two months. Comparative analysis was made on the clinical indicators of the experimental group and the control group. Results After treatment, the score of HAMD score and HAMA score in the experimental group was significantly lower than that in the control group, and the score of the experimental group was significantly lower than that in the control group, the differences were statistically significant (P< 0.05). The effective treatment efficiency of the patients in the experimental group was 86.84 ％ compared with the control group (73.68％), the differences were statistically significant (P< 0.05). There were 9 cases and 10 cases of adverse reactions between the experimental group and the control group, but there was no significant difference in the incidence of adverse reactions. Conclusion The liver capsule joint resolve depression escitalopram citalopram treatment of senile depression and anxiety comorbidities better clinical effect, can significantly improve the condition, improve the treatment efficiency, further promotion and application of clinical significance.
展开▼
